title: Severe myelotoxicity in a combination of gefitinib and vinorelbine.
authors.forename: Mana
authors.initials: M
authors.lastname: Yoshimura
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Nakamura
authors.forename: Fumio
authors.initials: F
authors.lastname: Imamura
authors.forename: Kiyonobu
authors.initials: K
authors.lastname: Ueno
authors.forename: Suguru
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Igarashi
mesh_terms: D000368:Aged; D000740:Anemia / Q000139:chemically induced*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced*; D010865:Pilot Projects; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D011799:Quinazolines; D014747:Vinblastine; D000077235:Vinorelbine; D000077156:Gefitinib